Matthew J. Frigault, M.d.

This early-phase study tested a personalized cell therapy called tisagenlecleucel in 13 patients with primary central nervous system lymphoma, a rare brain cancer. The main goal was to check safety, and researchers also looked at whether the treatment shrank tumors. Participants …